Chengdu Zhitian Bioengineering

Chengdu Zhitian Bioengineering is a Chinese biotechnology company specializing in the research, development, and production of recombinant protein therapeutics. The company is best known for its flagship commercial product, Recombinant Human Interleukin-2 (125 Ser), an immunotherapy agent approved for the treatment of various malignancies including renal cell carcinoma and melanoma. Established in 2001 and headquartered in Chengdu, the firm operates GMP-certified manufacturing facilities dedicated to biological engineering. Its business model encompasses the full lifecycle of biopharmaceutical production, from early-stage R&D to large-scale manufacturing and commercial distribution within the Chinese market.